Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Adverum Biotechnologies Is Soaring Today

By Maxx Chatsko - Feb 10, 2020 at 10:27AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Interim results from an early-stage study of its wet age-related macular degeneration treatment look promising.

What happened

Shares of Adverum Biotechnologies (ADVM -1.95%) rose as much as 40% Monday morning after the company reported updated interim results from a phase 1 study evaluating ADVM-022 as a potential treatment for wet age-related macular degeneration (AMD). Wet AMD is a chronic eye disease that causes blurred vision and blind spots. 

The company's gene therapy was administered as a high dose or a low dose. All six individuals who received the high dose were rescue injection-free at a median follow-up of 50 weeks. Four of the six individuals who received the low dose were rescue injection-free at a median follow up of 24 weeks. Prior to enrolling in the study, those individuals required an average of 9.3 injections per year. 

As of 11:24 a.m. EST, the pharma stock had settled to a 27.2% gain.

A man raising his arms in the air in celebration while he sits with his laptop.

Image source: Getty Images.

So what

The standard treatments for wet AMD are anti-VEGF drugs such as Avastin, Lucentis, and Eylea, which slow the growth of blood vessels central to the eye disorder's pathology. These drugs must be injected directly into the eye when used as rescue medications, and can produce several side effects. 

The inconvenience of current treatment options makes wet AMD an ideal target for one-time genetic medicines such as gene therapies. While wet AMD is not a genetic disorder, gene therapies aim to deliver the instructions for producing a protective protein within certain eye cells.

The interim results for ADVM-022 suggest that the drug candidate will be a competitor in the industry's wet AMD pipeline, which also includes a gene therapy candidate from Regenxbio and several next-generation monoclonal antibodies from heavyweights such as Roche.

Now what

Adverum Biotechnologies ended September with only $73 million in cash and reported an operating loss of $49 million in the first nine months of 2019. Therefore, investors shouldn't be too surprised if the company pulls the trigger on a public stock offering in the coming days to take advantage of its soaring stock price to raise much-needed funding. Beyond that, more results for ADVM-022 will be presented in 2020, which will now be closely watched by analysts and investors.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Adverum Biotechnologies, Inc. Stock Quote
Adverum Biotechnologies, Inc.
ADVM
$1.51 (-1.95%) $0.03
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.04 (-2.50%) $-1.05
REGENXBIO Inc. Stock Quote
REGENXBIO Inc.
RGNX
$33.12 (-4.44%) $-1.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.